Abstract Background and Objectives Second-generation antipsychotics (SGAs) for
schizophrenia show different risk profiles, whose evidence has been evaluated through …

Diabetes mellitus (DM) is a chronic health condition that is very prevalent worldwide. It has
been demonstrated that individuals with intellectual and developmental disabilities (IDDs) …

Objective (s): As olanzapine has side effects such as weight gain and metabolic disorders,
and alpha-mangostin has been shown to control metabolic disorders, the effects of alpha …

Amorphous and co-amorphous formulations have been used to enhance the solubility and
bioavailability of poorly water-soluble drugs. However, during handling and/or storage …

Objective To compare the largest set of bipolar disorder pharmacotherapies to date (102
drugs and drug combinations) for risk of diabetes mellitus (DM). Methods The IBM …

Background Although the association between short-term antipsychotics exposure and
triglycerides (TG) levels has been confirmed, the effects of long-term antipsychotics …

The work evaluates the stability of amorphous and co-amorphous olanzapine (OLZ) in
tablets manufactured by direct compression. The flowability and the compressibility of …

Background Olanzapine (OLZ) is an atypical antipsychotic agent for psychotic disorders.
Evidence has shown that OLZ is related to metabolic side effects, including obesity …

Schizophrenia is a challenging and common psychotic disorder that greatly affects the
quality of life of the affected patients. Patient compliance is among the major obstacles …

The antipsychotic drug olanzapine is associated with serious obesity side effects.
Hypothalamic astrocytes and associated toll-like receptor-4 (TLR4) signaling play an …